About Us
About Us
Leadership
Investors
Management Team
Michael T. Redman, Chief Executive Officer, Board Member
Mr. Redman is the CEO of Theratome and has served in this position since early 2023. Since joining Theratome, he has reorganized the company to be less research/grant focused and more focused on moving the products into human clinical trials and commercialization. He has acquired two new assets since joining the Company – an organ preservation technology and an additional product related to Acute Respiratory Distress Syndrome (ARDS). Both of these technologies were invented by Dr. March when employed at Indiana University. Furthermore, Mr. Redman is a co-inventor of the dry eye technology, which was filed as a provisional patent in August 2023. The dry eye development program is currently underway at the University of Florida under the guidance of Dr. March.
Mr. Redman has also championed the transition from a regenerative medicine company to a new focus combining the benefits of Artificial Intelligence with secretome regenerative medicine.
To further development efforts, Mr. Redman has raised sufficient capital to optimize its manufacturing process from two-dimensional tissue culture to three-dimensional bioreactors.
Prior to Theratome, Mr. Redman was a co-founder of GreenJay Therapeutics, where he served as its CEO from inception to August of 2023. During this timeframe, he structured the company and raised more than $1 million to advance its development of a new drug formulation that may have safety superiority compared to similar treatments for stem cell transplantation. During his tenure, he successfully consummated a manufacturing agreement with a CDMO that has extensive experience with the active ingredient and formulation experience.
Prior to GreenJay, Mr. Redman was the COO and Executive Vice President of Genprex, Inc., a gene therapy company focused on cancer and diabetes. During his tenure, he made changes to the manufacturing process that resulted in more than $14 million in savings due to substantial increases in yield (5 grams per lot to more than 62 grams of the DNA plasmid). Mr. Redman also recruited and set up the Company’s first clinical advisory board. Furthermore, he is the sole inventor of two new gene therapy drugs in development for indications in lung, colorectal cancer and malignant melanoma. Prior to Theratome, Mr. Redman served as the CEO of Oncolix, Inc., a company focused on breast and ovarian cancer. During his tenure, he raised approximately $15 million to fund operations. The company also went public under his leadership. The Company’s lead drug was suspended due to site reactions observed in human clinical trials although evidence of efficacy was observed.
He also served as CEO of Bone Medical, an Australian-based public company focused in the area of oral peptide delivery of products related to musculoskeletal disorders. Immediately prior to Bone Medical, Mr. Redman was the CEO and co-founder of Opexa Pharmaceuticals, which commenced operations in February of 2001, and was successfully sold to PharmaFrontiers Corporation in November of 2004 after leading the company through Phase II clinical trials. PharmaFrontiers later reorganized the company, which was named Opexa Therapeutics, a NASDAQ-listed company. The lead drug was subsequently licensed to Merck Serono in a $225 million deal that included upfront and milestone payments with a potential double-digit royalty.
His career spans over 30 years in the pharmaceuticals and biotechnology industry and encompasses leadership in sales, marketing, business, and commercial development. In addition to the three companies in which he served as CEO, Mr. Redman also held key management positions with Zonagen, Aronex Pharmaceuticals, Biovail, and American Home Products.
Mr. Redman has been instrumental in closing multiple pharmaceutical licensing deals, both domestic and international. These deals include in-licensing of university and NIH intellectual property, acquisitions, and divestitures. He is a former member of the Licensing Executives Society and served on its Executive Committee. Mr. Redman earned a BA in Biology from the University of Missouri and an MBA from the University of Phoenix.
Keith L. March, MD, PhD, FACC
Scientific Founder, Board Member
Dr. March has dedicated his career to bringing new medical approaches to patients. His publications include more than 170 manuscripts. He was the editor of the first book dedicated to cardiovascular gene transfer. Dr. March’s research has resulted in more than 60 worldwide (20+ U.S.) patents, with others pending. He invented the Closer, a widely-utilized patented suture-mediated closure device, used to close the puncture wound in an artery following heart catheterization. This device allows a patient to “walk off the table” after a catheterization without requiring prolonged bedrest. In 1999, Abbott Vascular, an affiliate of Abbott Laboratories, acquired the company that developed this technology; and the Closer approach has been used worldwide to treat more than 11,000,000 patients. He has served as a scientific advisor to numerous pharmaceutical, biotechnology and medical device companies.
Subsequently, he co-founded Theratome, based on a patented platform of technology originating in his laboratory that establishes the therapeutic factors secreted by stem cells as powerful therapeutics for critical medical needs.
His laboratory focuses on vascular biology, with a particular emphasis on the function and translational study of stem cells found in the adipose (fat) tissue, which his laboratory identified as cells with critical roles in blood vessel growth and control of inflammation. Dr. March is recognized as a leading expert in the field of adult stem cell research, particularly that involving adipose-derived stem cells. From 2008-2012, he was Chair of the National Institutes of Health Data and Safety Monitoring Board that oversees cell therapy trials in the areas of heart, lung, and blood diseases. Since 2012, he has been an investigator in the Cardiovascular Cell Therapy Research Network (CCTRN), involving seven lead centers in the USA working together to conduct NIH-sponsored cell therapy clinical trials. He has spearheaded FDA approval to conduct multiple U.S. trials employing one’s own fat-derived stem cells or umbilical cord lining-derived stem cells, including an ongoing trial to test these cells in the treatment of COVID-19, and three cell-based therapy trials authorized by FDA in early 2021, addressing critical medical needs in other pediatric and adult patient populations.
In addition to his research roles, Dr. March has served as the President (2007) of the International Federation of Adipose Therapeutics and Science (IFATS), and on the IFATS Board as well as other advisory committees and boards in the field. He continues to work to advance collaboration as well as public awareness about the significance of adult stem cells, and to provide consultative assistance in obtaining FDA approval for cell-based therapies. During the recent pandemic, he developed a complementary passion for advancing a disruptive digital health model using a high-touch patient-centered approach to improve wellness. This vision is being implemented by the team of Kindly Reminders, LLC, which is harnessing the power of empathy to develop patient engagement at a level far surpassing norms in the digital health industry.
Dr. March earned his BS degree in Biology/Chemistry from St. Francis College, Fort Wayne, Indiana, his PhD from Indiana University (Biochemistry), his MD from Indiana University (Internal Medicine) and a Cardiology Fellowship from the same institut
Michael Coleman, Chief Scientific Officer
Dr. Coleman has more than 29 years of experience as a research scientist and executive in the biotechnology, medical device, and pharmaceutical industries with a broad range of responsibilities that include leading product-focused research teams, heading the R&D function at a biotechnology subsidiary of a major pharmaceutical company, and serving as CEO of a start-up medical device company.
He has led the product development of three gene therapy products that progressed to clinical trials in the USA and overseen the clinical development of a fourth gene therapy product that successfully progressed through phase II trials in the USA and EU before partnering with a major pharma for phase III. In addition, he has been responsible for 2 510k approvals of medical devices in the USA, 2 CE Mark approvals of medical devices in the EU, and FDA IDE approval to conduct trials of a point-of-care cell therapy device.
He received his baccalaureate degree at Texas A&M University and doctoral degree at The Pennsylvania State University. He did postdoctoral research in Cell Biology at
Baylor College of Medicine. He is currently CEO of Metaclipse Therapeutics, an Atlanta-based, clinical stage biotech company developing immunotherapies for cancer and vaccines for infectious diseases and also serves as an advisor to multiple companies in the biotech space.
Jacob Agris, MD, PhD, Advisor
Dr. Agris is an academic physician, a leading scientist, a technology expert and an influential leader.
Dr. Agris is currently the Founder and Chief Medical Officer at iSensure and has been an Advisor and Chief Medical Officer to AiZtech, Imidex, Artrya and other digital healthcare companies. Previously he was the Chief Medical and Innovation Officer at Convatec where he provided clinical and scientific leadership during their transition to be a biologic company and was the Medical Digital Advisor to R&D at Bayer. In this role, he has established a vision and roadmap for the company’s radiology digital business and supports its 300-strong global radiology R&D team. He is responsible for the company’s digital radiology platform which serves 26 million patients per year and for the development of its artificial intelligence (Al) capabilities which received FDA breakthrough designation. His wider experience during his 12 years with Bayer includes a role as Head of Medical Affairs, in which he led teams designing and implementing clinical trials and gained regulatory approval for pharmaceuticals and medical devices from the FDA.
Prior to joining Bayer, Dr. Agris spent several years working in clinical roles. He was an interventional Neuroradiologist and was Co-director of the Stroke Program in the Saint Vincent Hospital System, and he was Assistant Professor and Head of interventional Neuroradiology at Virginia Commonwealth University Medical Center.
Dr. Agris holds both a Doctorate of Medicine from Baylor College of Medicine, and a Ph.D. in Electrical & Computer Engineering, which he completed at Rice University, funded by National Institutes of Health (NIH). He undertook postdoctoral medical training at several institutions including John Hopkins Hospital in Baltimore, Maryland in addition to post-doctoral research funded by the Keck foundation in Structural Biology at the NIH Center for Electron Microscopy and his novel work was published on the cover of Cell. He also holds a Bachelor of Science degree In Biomedical Engineering from Rensselaer Polytechnic Institute in New York State. He has over 100 abstracts/publications and patents related to healthcare.
Donald Payne, Chief Financial Officer
Mr. Payne has served as the Chief Financial Officer of Theratome Bio since June of 2023 and also serves as its Corporate Secretary. He is also the President and CEO of GreenJay Therapeutics and has been a part-time member of management of GreenJay since December 2022, and became President in August 2023. He has held various senior management positions in the Life Science Industry since 1992. He currently is a member of the Board of Directors of Ansun Biopharma, which is engaged in the development of fusion proteins for the treatment of viral diseases, and is a management and financial consultant to various organizations.
Mr. Payne most recently (2011 to early 2019) was responsible for managing clinical, regulatory, manufacturing and accounting matters for Oncolix, an oncology biotherapeutic engaged in the treatment of gynecological cancers. During this period he authored the IND and an Orphan Drug Application for ovarian cancer. Oncolix became a public reporting entity in 2017.
Mr. Payne previously was the founding President, CEO, and a Director of Nanospectra
development, US and foreign regulatory filings, and the commencement of human trials in prostate and head and neck cancers.
Mr. Payne has extensive experience with public and private financings and reporting. He received an MBA from Rice University in 1992, a BBA from Texas A&M University in 1976, and was a licensed CPA (Texas, 1978). He is a co-author of nine scientific publications and is a co-inventor of three issued or pending patent applications. He also held various advisory positions to academic and economic development entities.